Show simple item record

dc.contributor.authorBhide, SAen_US
dc.contributor.authorGulliford, Sen_US
dc.contributor.authorFowler, Jen_US
dc.contributor.authorRosenfelder, Nen_US
dc.contributor.authorNewbold, Ken_US
dc.contributor.authorHarrington, KJen_US
dc.contributor.authorNutting, CMen_US
dc.date.accessioned2018-06-05T14:27:50Z
dc.date.issued2010-10en_US
dc.identifier.citationRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2010, 97 (1), pp. 86 - 91en_US
dc.identifier.issn0167-8140en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1719
dc.identifier.eissn1879-0887en_US
dc.identifier.doi10.1016/j.radonc.2010.08.013en_US
dc.description.abstract<h4>Purpose</h4>This study describes the acute response of oral and pharyngeal mucosa to chemo-IMRT schedules using different doses per fraction.<h4>Materials and methods</h4>Patients, treated in prospective trials of concomitant chemo-IMRT with 2.17 Gy, 2.25 Gy and 2.4 Gy per fraction and identical dose of cisplatin, were included in this study. Acute toxicity was recorded prospectively using the CTCAE v2.0. We describe the incidence and prevalence of grade 3 oral mucositis and dysphagia over time and report the influence of overall treatment time (OTT). The association between the lengths of pharyngeal mucosa receiving 50 Gy (L50) and 60 Gy (L60) and grade 3 dysphagia was tested.<h4>Results</h4>The incidence and the peak prevalence of grade 3 dysphagia were significantly higher in patients receiving 2.4 Gy per fraction. The peak prevalence of grade 3 dysphagia was higher and the recovery was slower in patients with lower OTT (median 38 days vs. 42 days) treatment. There was a significant correlation between L50, L60 and grade 3 dysphagia. A L50 and L60 greater than 8 cm resulted in greater than 60% and 70% incidence of grade 3 dysphagia, respectively.<h4>Conclusion</h4>The length of pharyngeal mucosa receiving doses close to the prescription dose correlates with grade 3 dysphagia. It was observed that incidence of grade 3 dysphagia was lower and recovery from it was quicker in patients with greater OTT.en_US
dc.formatPrint-Electronicen_US
dc.format.extent86 - 91en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectPharynxen_US
dc.subjectMouth Mucosaen_US
dc.subjectHumansen_US
dc.subjectCarcinoma, Squamous Cellen_US
dc.subjectHead and Neck Neoplasmsen_US
dc.subjectDeglutition Disordersen_US
dc.subjectStomatitisen_US
dc.subjectCisplatinen_US
dc.subjectFluorouracilen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectRadiotherapy Dosageen_US
dc.subjectPrevalenceen_US
dc.subjectProspective Studiesen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectMiddle Ageden_US
dc.subjectFemaleen_US
dc.subjectMaleen_US
dc.subjectRadiotherapy, Intensity-Modulateden_US
dc.subjectDose Fractionation, Radiationen_US
dc.titleCharacteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy.en_US
dc.typeJournal Article
dcterms.dateAccepted2010-08-18en_US
rioxxterms.versionofrecord10.1016/j.radonc.2010.08.013en_US
rioxxterms.licenseref.startdate2010-10en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncologyen_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radiotherapy Physics Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume97en_US
pubs.embargo.termsNot knownen_US
icr.researchteamRadiotherapy Physics Modellingen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen_US
dc.contributor.icrauthorGulliford, Sarahen_US
dc.contributor.icrauthorNutting, Chrisen_US
dc.contributor.icrauthorBhide, Shreerangen_US
dc.contributor.icrauthorNewbold, Kateen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record